Introduction
T cells can be genetically modified to express chimeric antigen receptors (CARs). [1] [2] [3] [4] [5] CARs consist of an antigen-recognition moiety, such as antibody-derived, single-chain variable fragments, coupled to T-cell activation domains. [1] [2] [3] [4] T cells have been genetically engineered to express CARs that can recognize a variety of tumor-associated antigens, including the B-lineage antigen CD19, in a non-human leukocyte antigen-restricted manner. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Expression of the cell-surface protein CD19 is restricted to normal mature B cells, malignant B cells, B-cell precursors, and plasma cells. [16] [17] [18] [19] We have designed a CAR that targets CD19 and initiated a clinical trial of autologous T cells expressing this CAR (www.clinicaltrials. gov; #NCT00924326).
Methods
This clinical trial was approved by the National Cancer Institute Institutional Review Board. Design and construction of the mouse stem cell virus-based splice-gag retroviral vector MSGV-FMC63-28Z encoding the anti-CD19 CAR used in our clinical trial have been described (GenBank HM852952). 7 The anti-CD19 CAR contains an antigen-recognition moiety consisting of the variable regions of the FMC63 monoclonal antibody joined to part of the CD28 molecule and the signaling domains of the CD3 molecule.
Peripheral blood mononuclear cells were transduced with retroviruses encoding the anti-CD19 CAR and cultured in an almost identical manner as previously described. 20 As measured by flow cytometry, the CAR was expressed on 64% of the infused cells, which were 98% CD3 ϩ T cells (supplemental Figure 1 , available on the Blood Web site; see the Supplemental Materials link at the top of the online article). The T cells were 66% CD8 ϩ and 34% CD4 ϩ . The anti-CD19-CAR-transduced T cells specifically recognized CD19 ϩ target cells (supplemental Table 1 ). Methods of T-cell preparation, flow cytometry, polymerase chain reaction, and immunohistochemistry are in the supplemental data. For the immunohistochemistry images in Figures 1 and 2 , images were obtained via digital microscopy using an Olympus BX51 microscope (Olympus America) equipped with a UPlanFL 10ϫ/0.3 numeric aperture and UPlanFL 40ϫ/0.75 numeric aperture objectives. Images were captured using an Olympus DP70 digital camera system. Imaging software was Adobe Photoshop CS3 (Adobe Systems).
Results and discussion
The patient was diagnosed with grade 1, stage IVB follicular lymphoma in 2002. Before enrollment on our protocol, he had received the following treatments for his lymphoma: PACE (prednisone, doxorubicin, cyclophosphamide, and etoposide), an idiotype vaccine, the anti-CTLA-4 monoclonal antibody ipilimumab, and EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab). The last cycle of EPOCH-R was administered in January 2008. The EPOCH-R caused a partial remission; however, progressive disease was noted in July 2008. The patient received no further treatment before he was evaluated for enrollment on our trial of anti-CD19-CAR-transduced T cells.
When we evaluated the patient in May 2009, he had progressive lymphoma that involved all major lymph node areas ( Figure 1A ). He had bilateral pleural effusions, night sweats, and a recent weight loss of 10 pounds. Flow cytometry of a fine needle aspirate from an The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked ''advertisement'' in accordance with 18 USC section 1734.
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BLOOD, 18 NOVEMBER 2010 ⅐ VOLUME 116, NUMBER 20 For personal use only. on April 15, 2017 . by guest www.bloodjournal.org From enlarged cervical lymph node demonstrated a monoclonal B-cell process consistent with follicular lymphoma that uniformly expressed CD19, CD20, CD22, CD10, and IgM-kappa. Flow cytometry showed that 14.5% of the blood lymphoid cells had a phenotype that was consistent with the lymphoma and 0.7% of the blood lymphoid cells were normal polyclonal B cells (data not shown). Before treatment, 35% of bone marrow lymphoid cells expressed CD19 ( Figure 1B) . A total of 55% of these CD19 ϩ cells were monoclonal -positive and -negative lymphoma cells; 45% of the bone marrow CD19 ϩ cells were normal surface-immunoglobulin (Ig)-negative immature B-cell precursors ( Figure 1C ). The immature B-cell precursors demonstrated a pattern of antigen expression consistent with normal maturation, namely, CD22 ϩ B cells with decreasing CD10 expression correlating with increasing CD20 expression ( Figure 1D-E) . 21, 22 Large numbers of bone marrow CD19 ϩ cells and CD79a ϩ cells were detected by immunohistochemistry before treatment ( Figures 1G, 2A) .
The patient underwent apheresis, and peripheral blood mononuclear cells were used to prepare anti-CD19-CARtransduced T cells. The patient received a lymphocyte-depleting regimen consisting of 60 mg/kg cyclophosphamide daily for 2 days followed by 5 daily doses of 25 mg/m 2 fludarabine. The day after the last fludarabine dose, the patient received 1 ϫ 10 8 anti-CD19-CAR-transduced T cells intravenously. The next day, he received 3 ϫ 10 8 anti-CD19-CAR-transduced T cells intravenously. After the second anti-CD19-CAR-transduced T-cell infusion, the patient received 720 000 IU/kg interleukin-2 (IL-2) intravenously every 8 hours. Eight doses of IL-2 were administered. The only acute toxicities that the patient experienced were cytopenias that were attributable to chemotherapy and a fever that lasted 2 days (maximum temperature, 38.5°C). The patient was discharged 11 days after his second anti-CD19-CAR-transduced T-cell infusion, and he resumed full-time employment.
After therapy, computed tomography scans revealed an impressive partial remission of the lymphoma that lasted 32 weeks ( Figure  1A) ; 32 weeks after treatment, progressive CD19 ϩ lymphoma was noted in right cervical and retroperitoneal lymph nodes.
Blood B cells were absent from 9 weeks after anti-CD19-CARtransduced T-cell infusion until at least 39 weeks after anti-CD19-CARtransduced T-cell infusion ( Figure 2C ; supplemental Figure 2 ). This prolonged B-cell depletion cannot be attributed to the chemotherapy that the patient received. Neither the New York esophageal squamous cell carcinoma antigen-1 (NY-ESO) nor the melanoma antigen gp100 is expressed by B cells. 23, 24 In prior clinical trials, patients treated with the same chemotherapy and IL-2 regimen as the patient described in this report along with T cells retrovirally transduced with receptors that recognized either NY-ESO or gp100 did not experience prolonged B-cell depletion ( Figure 2D ).
Except for B cells and a mild thrombocytopenia, all blood cell counts, including neutophils, erythrocytes, T cells, and NK cells, of the patient treated with anti-CD19-CAR-transduced T cells recovered to normal levels by 9 weeks after treatment ( Figure 2E-F) .
Thirty-six weeks after anti-CD19-CAR-transduced T cells were infused, CD19 ϩ cells were absent from the bone marrow as measured by flow cytometry ( Figure 1F ) and immunohistochemistry ( Figure  1H-I) . CD79a ϩ cells were undetectable in the bone marrow by immunohistochemistry 14 weeks after treatment (data not shown). CD79a ϩ cells were detected at greatly below normal frequency 36 weeks after anti-CD19-CAR-transduced T-cell infusion ( Figure 2B ). CD79a is expressed earlier in B-cell development than CD19, 25 so the presence of a small number of CD79a ϩ cells while CD19 ϩ cells were absent suggests early recovery of B-lineage cells.
A decrease in serum IgG levels occurred after treatment ( Figure  2G ). Serum IgM was undetectable from 9 to at least 39 weeks after treatment. Serum IgA was 66.8 mg/dL before treatment. Serum IgA decreased to below the detectable limit of 10 mg/dL after treatment (supplemental Figure 3) . Five months after treatment, the patient developed pneumonia of unknown etiology that required hospitalization. After a course of antibiotics, the patient recovered completely. The patient has subsequently received intravenous Ig replacement, and he has not had further infections.
The anti-CD19 CAR transgene was detected in peripheral blood mononuclear cells from one to 27 weeks after anti-CD19-CARtransduced T-cell infusion with a quantitative real-time polymerase chain reaction assay ( Figure 2H) . This is the first patient treated on our trial and the only patient with long enough follow-up to evaluate B-cell depletion. The prolonged elimination of CD19 ϩ cells in this patient indicates in vivo antigen-specific activity of anti-CD19-CAR-expressing T cells. Our findings should encourage continued study of anti-CD19-CARtransduced T cells. 
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